TURBO OPTIONSSCHEIN - VIVORYON THERAPEUTICS | Market Closed - Börse Stuttgart 02:14:12 2024-05-24 am EDT | ||
| 0.87 EUR | +42.62% |
|
| Current month | +135.14% | ||
| 1 month | +163.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 0.87 | +42.62% |
| 24-05-23 | 0.61 | +48.78% |
| 24-05-22 | 0.41 | -4.65% |
| 24-05-21 | 0.43 | +2.38% |
| 24-05-20 | 0.42 | +16.67% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 02:14 am EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX3Y69 |
| ISIN | DE000LX3Y698 |
| Date issued | 2024-03-06 |
| Strike | 0.4 € |
| Maturity | 2024-12-12 (200 Days) |
| Parity | 1 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.87 € |
|---|---|
| Lowest since issue | 0.03 € |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.11
EUR
Average target price
41.57
EUR
Spread / Average Target
+1,869.98%
- Stock Market
- Certificates
- Certificat
